Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 4/20 | 0.51 |
| ▸ | FLT3 | P36888 | 4/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.51 |
| ▸ | BAD | Q92934 | 3/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375355 | 0.79 | ULK1 (0.74) | ULK1PTK2CDK7CDK9 | |
| SCHEMBL1203252 | 0.78 | ULK1 (0.59) | ULK1PTK2CDK7CDK9 | |
| SCHEMBL13395038 | 0.77 | ULK1 (0.61) | ULK1PTK2KMT2APLK1CDK7 | |
| SCHEMBL9776701 | 0.77 | SLC2A1 (0.59) | PDE5AAPP | |
| SCHEMBL28533410 | 0.77 | PDE5A (0.46) | PTK2MEN1KMT2ACDK7CDK9 | |
| SCHEMBL375665 | 0.77 | ULK1 (0.58) | ULK1PIM1PTK2CDK7CDK9 | |
| SCHEMBL12627646 | 0.77 | ULK1 (0.58) | ULK1PIM1FLT3PIM2BAD | |
| SCHEMBL30086235 | 0.77 | ULK1 (0.58) | ULK1PIM1FLT3PIM2BAD | |
| SCHEMBL29900878 | 0.77 | ULK1 (0.58) | ULK1PIM1PTK2CDK7CDK9 | |
| SCHEMBL1203432 | 0.77 | ULK1 (0.58) | ULK1PIM1FLT3PIM2BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ULK1 3381/4885PIM1 243/4885FLT3 8/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ULK1 3381/4885PIM1 243/4885FLT3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.